Literature DB >> 35310770

Possibility of Relapse of COVID19 in Asymptomatic Cases and Risk Assessment.

Kirtimaan Syal1,2.   

Abstract

Entities:  

Year:  2022        PMID: 35310770      PMCID: PMC8922088          DOI: 10.1007/s12291-022-01029-9

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


× No keyword cloud information.
Sir, The rapid spread of COVID19 has been attributed to its asymptomatic presentation and poor diagnosis [1, 2]. The correlation between antibody response and the severity of COVID19 has been well-established [3]. Zhou et al. have reported that low titres of antibodies against SARS-CoV-2 can possibly lead to the relapse of COVID-19 [4]. Notably, the measurement of IgG alongside monitoring of the symptoms in patients with co-morbidities can potentially facilitate the assessment of the possibility of the relapse of COVID19 [4]. Recently, Marchi et al. concluded that most asymptomatic cases do not develop detectable levels of antibodies [5]. In the light of these evidences, Kiran Kumar et al. [6] results become highly relevant where they have shown the correlation of the levels of IgG antibody with cough, age and duration of the hospital stay in 210 patients. This study has the potential to reconfigure our understanding of the pathophysiology of COVID19. Though the convalescent plasma therapy is no more recommended by the ICMR and has been removed from their guidelines, the importance of assessment of antibodies in the primary subject  cannot be undermined as it can enable risk management for relapse of COVID19. However, this study needs to be corroborated with a larger study. Like others, Kiran Kumar et al. [6] have also reported many COVID19 subjects without antibody immune responses and such subjects could be at a risk of relapse. Further, the assessment of different inflammatory markers and antibodies should be preferably done at distinct time points for each patient in a larger group. Usually, different patients give inflammatory responses in diverse chronological dimensions, and evaluation of markers at one-time point should not be compared. Further, the genetic basis of such diverse immunological response should be explored. They have rightly concluded that the severity of COVID19 is independent of the type of blood group; nonetheless, blood groups have been shown to influence the susceptibility to COVID19 infection [7]. Lastly, it should be considered that asymptomatic COVID19 patients with co-morbidities due to lack of antibodies could still be at a high risk of re-infection by SARS-CoV-2 and should take all precautions especially taking into account the emergence of newer genetic variants and mutants.
  7 in total

1.  The effects of blood group types on the risk of COVID-19 infection and its clinical outcome

Authors:  Hakan Göker; Elifcan Aladağ Karakulak; Haluk Demiroğlu; Çağlayan Merve Ayaz Ceylan; Yahya Büyükaşik; Ahmet Çağkan Inkaya; Salih Aksu; Nilgün Sayinalp; Ibrahim Celalettin Haznedaroğlu; Ömrüm Uzun; Murat Akova; Osman Ilhami Özcebe; Serhat Ünal
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

2.  A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.

Authors:  Vincent Legros; Solène Denolly; Manon Vogrig; Bertrand Boson; Eglantine Siret; Josselin Rigaill; Sylvie Pillet; Florence Grattard; Sylvie Gonzalo; Paul Verhoeven; Omran Allatif; Philippe Berthelot; Carole Pélissier; Guillaume Thiery; Elisabeth Botelho-Nevers; Guillaume Millet; Jérôme Morel; Stéphane Paul; Thierry Walzer; François-Loïc Cosset; Thomas Bourlet; Bruno Pozzetto
Journal:  Cell Mol Immunol       Date:  2021-01-06       Impact factor: 11.530

3.  SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience.

Authors:  Pvsn Kiran Kumar; Mithu Banerjee; Archana Bajpayee; Saptarishi Mandal; Prasenjit Mitra; Praveen Sharma; Sanjeev Misra; Pankaj Bhardwaj
Journal:  Indian J Clin Biochem       Date:  2021-11-18

4.  Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.

Authors:  Serena Marchi; Simonetta Viviani; Edmond J Remarque; Antonella Ruello; Emilio Bombardieri; Valentina Bollati; Gregorio P Milani; Alessandro Manenti; Giulia Lapini; Annunziata Rebuffat; Emanuele Montomoli; Claudia M Trombetta
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

5.  Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report.

Authors:  Xiaoxi Zhou; Jianfeng Zhou; Jianping Zhao
Journal:  BMC Infect Dis       Date:  2020-07-11       Impact factor: 3.090

6.  COVID-19: Herd immunity and convalescent plasma transfer therapy.

Authors:  Kirtimaan Syal
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

7.  Guidelines on newly identified limitations of diagnostic tools for COVID-19 and consequences.

Authors:  Kirtimaan Syal
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

  7 in total
  2 in total

Review 1.  Vitamin C and its therapeutic potential in the management of COVID19.

Authors:  Neethu Rs; M V N Janardhan Reddy; Sakshi Batra; Sunil Kumar Srivastava; Kirtimaan Syal
Journal:  Clin Nutr ESPEN       Date:  2022-06-04

2.  An Unusual Presentation of Superior Mesenteric Venous Occlusion in Mild COVID-19.

Authors:  Sakshi Batra; Asha G Nair; Kirtimaan Syal
Journal:  Indian J Clin Biochem       Date:  2022-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.